Rituximab | Etanercept | Adalimumab/infliximab | ||||||
---|---|---|---|---|---|---|---|---|
DAS28 | Mean (SD) | N† | Mean (SD) | N† | p Value* | Mean (SD) | N† | p Value* |
6 months | −1.61 (1.56) | 221 | −1.32 (1.41) | 108 | 0.19 | −1.04 (1.33) | 143 | 0.001 |
9 months | −1.35 (1.54) | 78 | −1.66 (1.44) | 50 | 0.79 | −1.39 (1.48) | 72 | 0.36 |
12 months | −1.81 (1.60) | 121 | −1.66 (1.49) | 78 | 0.36 | −1.55 (1.49) | 104 | 0.05 |
*p Value compared with rituximab.
†Number of patients with data available at time intervals defined in the Methods section.